Wall Street Bulls Look Optimistic About Teradyne (TER): Should You Buy?

19.03.25 14:30 Uhr

Werte in diesem Artikel
Aktien

82,32 EUR -0,73 EUR -0,88%

Indizes

5.703,1 PKT -73,6 PKT -1,27%

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Teradyne (TER).Teradyne currently has an average brokerage recommendation (ABR) of 1.69, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 16 brokerage firms. An ABR of 1.69 approximates between Strong Buy and Buy.Of the 16 recommendations that derive the current ABR, 12 are Strong Buy, representing 75% of all recommendations.Brokerage Recommendation Trends for TERCheck price target & stock forecast for Teradyne here>>>The ABR suggests buying Teradyne, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.Is TER Worth Investing In?Looking at the earnings estimate revisions for Teradyne, the Zacks Consensus Estimate for the current year has declined 12.4% over the past month to $3.43.Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for Teradyne. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Therefore, it could be wise to take the Buy-equivalent ABR for Teradyne with a grain of salt.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teradyne, Inc. (TER): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Teradyne und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Teradyne

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teradyne

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Teradyne Inc.

Wer­bung

Analysen zu Teradyne Inc.

DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
DatumRatingAnalyst
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
24.01.2018Teradyne BuyStifel, Nicolaus & Co., Inc.
05.07.2017Teradyne BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
21.11.2017Teradyne HoldDeutsche Bank AG
29.10.2015Teradyne Sector WeightPacific Crest Securities Inc.
11.06.2012Teradyne neutralUBS AG
DatumRatingAnalyst
30.07.2009Teradyne ErsteinschätzungMorgan Stanley
22.12.2008Teradyne underweightJP Morgan Chase & Co.
06.12.2005Update Teradyne Inc.: UnderperformGoldman Sachs
06.12.2005Teradyne underperformGoldman Sachs

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teradyne Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen